Objective: We investigated the link between DNA hypomethylation and clinical penetrance in facioscapulohumeral dystrophy (FSHD) because hypomethylation is moderate and heterogeneous in patients and could not thus far be correlated with disease presence or severity.
DNA methylation, a covalent addition of methyl groups to the carbon 5 position of cytosine within CpG dinucleotides, has important roles in several physiologic processes [1] [2] [3] [4] but also contributes to a number of diseases. 5, 6 A large fraction of the human genome corresponds to CpG-rich repetitive sequences, the majority of which are packed as condensed and repressed chromatin by DNA methylation. 7 Hypomethylation of repetitive DNA has multiple consequences; aberrant DNA methylation of repetitive sequences has a causal role in a variety of diseases including rare constitutive diseases such as facioscapulohumeral dystrophy (FSHD). 8, 9 FSHD is an autosomal dominant myopathy characterized by a progressive and asymmetric weakening of facial, shoulder, and upper body muscles with a progression to the lower body. Specific groups of muscles are affected but the underlying pathomechanism is not fully understood. At the molecular level, the pathology is linked to the deletion of an integral number of repetitive macrosatellite elements (D4Z4; figure 1A ) at the 4q35 subtelomeric locus. In the general population, the number of D4Z4 repeats ranges from 11 to up to 100-150 copies, whereas in most patients, this number is below the threshold of 11 copies. D4Z4 is extremely GC rich (70%) and methylated in normal individuals but hypomethylated in patients with FSHD [9] [10] [11] [12] [13] and in patients with phenotypic FSHD (FSHD2) carrying long D4Z4 arrays on both chromosomes 4. 14 However, the link between D4Z4 hypomethylation and FSHD is still unclear.
METHODS To investigate the link between presence or total absence of clinical signs of FSHD and D4Z4 methylation level, we explored a cohort of 37 FSHD1, 9 FSHD2, 20 nonsymptomatic noncarrier individuals (controls), and 29 nonsymptomatic carriers of a shortened D4Z4 array (,11 units) by implementing 2 complementary approaches: methylated DNA immunoprecipitation (MeDIP) and sodium bisulfite sequencing (figure 1B). We provide Class III evidence that assays for D4Z4 methylation distinguish patients with FSHD from asymptomatic carriers.
Standard protocol approvals, registrations, and patient consents. All individuals provided written informed consent for the use of their DNA sample for medical research. The study was performed in accordance with the Declaration of Helsinki. Controls (table e-1 on the Neurology ® Web site at Neurology.org) were either randomly selected individuals or were patients' relatives who did not in either case carry a short D4Z4 array nor were affected by any muscular pathology (details in tables e-2-e-5 and supplementary materials). Controls were selected in the same age range and sex representation as test subjects.
Detailed e-Methods are given in the supplementary information section.
RESULTS FSHD is characterized by a high interindividual and intrafamilial variability in the age at onset and course of the disease. Penetrance of the symptoms is estimated between 80% and 95% at the age of 20 to 30 years, but significantly higher in men than women. Furthermore, an inverse correlation between the number of residual repeats and the penetrance has been proposed but numerous cases of asymptomatic individuals carrying a low number of repeats have been reported. [15] [16] [17] [18] [19] To evaluate to what extent D4Z4 methylation changes are associated with the presence or absence of clinical signs of FSHD, we developed and tested 2 approaches, MeDIP and sodium bisulfite sequencing, on a large cohort of clinically affected patients with FSHD carrying a shortened D4Z4 array (FSHD1), patients with phenotypic FSHD (FSHD2), and controls. Furthermore, we also addressed whether D4Z4 methylation might explain the discrepancy in the clinical expression of the pathology by analyzing the D4Z4 methylation pattern in 29 asymptomatic carriers.
Among a number of protocols for measuring DNA methylation, bisulfite sequencing stands out for its reliability in quantifying the DNA methylation status at a single nucleotide resolution in heterogeneous samples. This methodology depends on the oxidative deamination of cytosines into uracils upon treatment by sodium bisulfite while methylated cytosines remain (figure 1B, table e-6). Bisulfite-treated samples are then amplified by PCR using sequencespecific primers designed to amplify methylated and unmethylated DNA with the same efficiency. 20 The multiple DNA fragments are subcloned and sequenced allowing analysis of the methylation status/CpG/DNA molecule (figure 1B). Because bisulfite sequencing is a time-consuming and resource-intensive method, we also evaluated the level of DNA methylation with a less direct and less sensitive approach by using immunoprecipitation of methylated DNA fragments (MeDIP) followed by quantitative PCR ( figure 1B , table e-6). Technical performance of both methods was first analyzed by comparing different clones of the HCT116 colon cancer cell line. We applied either bisulfite sequencing (figure 2, A-C) or MeDIP ( figure 2D ) to DNA from parental HCT116, HCT116 in which the DNA methyltransferase 3b had been invalidated (HCT116 3b KO), or HCT116 in which both DNA methyltransferases 1 and 3b had been invalidated (HCT116 dKO). 21 We observed an almost complete hypomethylation of D4Z4 in the dKO cells compared with the parental cells by both methods. We observed an intermediate methylation pattern for the 3b KO cells suggesting that both DNA methyltransferases are required to maintain a high level of methylation along the D4Z4 sequence but also for 2 other macrosatellite repeats (DXZ4 on chromosome X, RS447 on chromosome 4).
Then, to evaluate the link between DNA methylation and the presence or absence of clinical signs of FSHD, we investigated the level of DNA methylation by MeDIP followed by quantitative PCR for 3 regions within D4Z4 in 37 FSHD1 cases (number of repeats ranging from 2 to 10), 29 asymptomatic carriers in the same range for D4Z4 units, 9 phenotypic FSHD (FSHD2) cases, and 20 controls (figure 3A). Using a nonparametric pairwise comparison, we determined that enrichment in methyl groups is significantly decreased in patients with phenotypic FSHD (FSHD2) and FSHD1 compared with asymptomatic carriers. In addition, we performed a multivariate analysis (principal component analysis [PCA] ) to evaluate the correlations between the level of methylation in the different D4Z4 subregions with sex, age, number of repeats, and presence or absence of symptoms in the 4 different subgroups of samples. As expected, the presence of symptoms correlated with a low number of D4Z4 repeats (Pearson correlation coefficient, r 5 20.333; p 5 0.004). A low methylation level in the 59 and 39 regions of D4Z4 was observed in patients with clinical FSHD symptoms (Pearson correlation coefficient, r 5 20.547; p , 0.0001, and r 5 20.446; p , 0.0001, respectively). By comparing the different groups, we did not observe any strong correlation (.0.5) between hypomethylation and age or sex. The MeDIP data do suggest that the mid region is more methylated in females than in males (r 5 20.308; p 5 0.008), but that sex may also correlate with Ct method between the input (total DNA after shearing) and immunoprecipitated DNA. Values were normalized to a single copy intergenic sequence on chromosome 5 containing a single CpG site. To validate the sensitivity of the method, we compared methylation profiles in HCT116, HCT116 3b KO, and HCT116 dKO cell lines. Experiments were done in triplicate and the SD is shown (error bars). The level of methylation was also determined by MeDIP for 2 other macrosatellite repeats (DXZ4 and RS447).
penetrance (table e-7) . Notably, this significant change in the average methylation level between symptomatic and asymptomatic FSHD is not observed genome-wide but is restricted to D4Z4 because we did not observe any significant difference in the level of methylation for the short interspersed AluI repeats dispersed throughout the genome both in euchromatin and heterochromatin regions and reflecting the global genomic methylation (figure 3B).
Therefore, we concluded that hypomethylation is not only a function D4Z4 residual number, but also reflects the presence of clinical signs of the disease because differences were observed between individuals with FSHD and nonaffected individuals including asymptomatic carriers and controls.
To confirm the hypothesis of a link between methylation level and clinical expression, we surveyed how methylation is transmitted within a few families comprising FSHD cases, asymptomatic carriers, and nonsymptomatic noncarriers by combining results obtained by MeDIP and/or sodium bisulfite sequencing (figure 4). Analysis of normalized MeDIP and bisulfite data confirms a decrease in methylation/ CpG at the 59 end of D4Z4 in individuals affected with FSHD, which is not correlated with hypomethylation of other macrosatellites or global methylation of the genome at AluI sequences.
Thus, to obtain a more precise understanding of the DNA methylation pattern in the different groups, we analyzed by sodium bisulfite sequencing 3 different regions within D4Z4 (figure 5A) in controls, individuals with symptomatic FSHD1, asymptomatic carriers, and individuals with phenotypic FSHD. For each sample, 10 individual clones with a percentage of conversion .95% were analyzed (figures e-1-e-3). As observed in a recent study evaluating the methylation profile of the D4Z4 repeats in a small number of patients with phenotypic FSHD by bisulfite sequencing (i.e., 12 patients with FSHD2 carrying normalsized 4qA alleles), 22 we observed a marked decrease in Decreased D4Z4 methylation is associated with facioscapulohumeral dystrophy symptoms in families with variable penetrance
We compared the level of methylation of D4Z4 (left graphs) and other repetitive sequences (middle graph) for 4 families for which variable penetrance has been reported from one generation to another between nonsymptomatic carrier parents (in whom mosaicism has been excluded above a 4% level) and affected descendants (E, D, B, and C) by methylated DNA immunoprecipitation Comparison of patients with FSHD1 and asymptomatic carriers reveals differences in the methylation of the proximal region of D4Z4 DNA methylation in FSHD2 in the proximal part of the repeat ( figure 5C ). Moreover, combination of the percentage of methylation for the different clones in the different subgroups revealed that the level of methylation is similar in FSHD1 and FSHD2. Significant differences were observed between controls and FSHD1 or FSHD2 for the most proximal sequence (BIS-59) (figure 5, B and C). Strikingly, using a nonparametric Kruskal-Wallis test, a significant difference in the percentage of methylated DNA molecules was also observed between asymptomatic FSHD carriers and patients with FSHD1 or FSHD2 ( figure 5C ). In addition to the proximal hypomethylated region, a significant hypomethylation was also observed in the 39 end of the D4Z4 repeat in FSHD2 compared with FSHD1 ( figure 5C Moreover, PCA taking into account the presence or absence of symptoms and the percentage of methylation for each individual CpG revealed that the disease is mainly associated with a decrease methylation of a few CpGs within the 59 region (CpG, 1; 2; 5; 7; 10; 11; 15; 20; Pearson correlation coefficient 20.379 , r , 20.498; 0.047 , p value , 0.007).
Our results indicate that the degree of D4Z4 hypomethylation is not directly correlated with shortening of the array but suggest a direct correlation between hypomethylation and the presence of clinical signs of the disease. Furthermore, hypomethylation is not uniformly spread across the D4Z4 repeat but confined to discrete regions or specific sites, suggesting a complex regulatory mechanism, which remains to be investigated. DISCUSSION We aimed to identify regions within D4Z4 differentially methylated in individuals with FSHD and asymptomatic individuals carrying a shortened pathogenic array. By investigating a large collection of 95 samples including controls, individuals with FSHD, asymptomatic carriers, and patients with FSHD2 using 2 methods, immunoprecipitation of methylated CpGs (MeDIP) and sodium bisulfite sequencing, we reasoned that specific methylation changes might shed light on disease-associated alterations linked to disease penetrance or onset.
So far, methylation status of either the most proximal or the most distal D4Z4 repeat has been mainly analyzed by Southern blotting after digestion with 3 methylation-sensitive enzymes, BsaAI, FseI, and CpoI, allowing analysis of only a few CpG sites. In patients with FSHD, hybridization with a DNA probe corresponding to the proximal unique sequence upstream of the first D4Z4 repeat [9] [10] [11] 13, 23 shows a decreased methylation of approximately 10% to 30% compared with controls, indicating that epigenetic changes are involved in the pathology.
Both sodium bisulfite sequencing and MeDIP remain more resolutive than approaches based on the capacity of methyl-sensitive restriction enzymes to cleave a single recognition site within a specific DNA sequence. Because of the high CpG density of the D4Z4 repeat, MeDIP is well adapted, while this method is less sensitive for bulk DNA in which CpG sites are more dispersed. 24, 25 By MeDIP, we observed significant differences between controls and carriers of a short 4qA allele (,11 units) but asymptomatic for the pathology and individuals with FSHD. However, this method did not permit identification of specific hypomethylated sites.
Therefore, we also assessed the methylation level across the D4Z4/CpG/DNA molecule at a single base resolution by bisulfite sequencing. This assay revealed a marked hypomethylation in the proximal and distal part of D4Z4 for FSHD2 and the proximal part of the repeat for FSHD1 with specific differences between asymptomatic carriers and patients with FSHD even in the same family. These differences seem specific for D4Z4 because they were not observed genome-wide for dispersed AluI elements or for other clustered tandem macrosatellite repeats (RS447, DXZ4).
In the majority of individuals carrying 1 to 3 D4Z4 units, penetrance is considered as almost complete at age 50 years, while in patients carrying between 4 and 8 repeated units, the risk of developing symptoms is 55% to 63% at the age of 50. 26 Differential methylation is also observed between symptomatic and asymptomatic individuals with a low number of D4Z4 units (5 units) and in individuals for whom first-degree relatives have been diagnosed at a younger age. The differences in the degree of hypomethylation are not biased by the age at onset as described in the literature for heterochromatic regions and repetitive sequences because, on average, individuals in the asymptomatic group are older (mean age 5 52.6 years) than in the control (mean age 5 47.5 years) or FSHD1 (mean age 5 43.6 years) groups.
FSHD is characterized by a highly variable disease progression, incomplete penetrance, and a marked interindividual and intrafamilial heterogeneity. 15, 16, 27, 28 By analyzing the degree of methylation in different families, we also show that methylation level is not stably transmitted together with the number of repeats among individuals in the same family but that hypomethylation is mainly observed in individuals harboring FSHD symptoms. However, our results also suggest that the differential methylation between asymptomatic carriers and patients with FSHD1 might be influenced by sex, but this aspect would require further investigations on a larger cohort.
A key question regarding FSHD is whether hypomethylation is a cause or consequence of D4Z4 array shortening in FSHD1. Here, hypomethylation is not directly correlated with the number of repeats suggesting that in FSHD1, hypomethylation is not a mere consequence of D4Z4 array shortening and that the clinical phenotype might be determined by the epigenetic changes rather than Mendelian inheritance in both FSHD1 nonsymptomatic carriers of short D4Z4 stretches and patients with FSHD2 who have normal D4Z4 arrays.
The focal rather than global and random hypomethylation of D4Z4 in patients with FSHD1 and FSHD2 22 in the proximal or distal part of the repeat suggests an active and targeted mechanism. The current hypothesis explaining the FSHD pathomechanism is the production in affected individuals of a long DUX4 transcript encoded by the last D4Z4 and the distal 4qA region. We did not observe any significant hypomethylation in the region encompassing the DUX4 promoter sequence (mid) and the DBE element, 29, 30 but it remains to be determined whether focal demethylation of only a few CpGs upstream or downstream induces DUX4 expression in patients with FSHD or whether hypomethylation across the whole D4Z4 array globally modifies the chromatin of the 4q35 region and expression of other genes. Notably, we also observed a high rate of sequence variation at CpGs especially in the mid (18%) and 39 (16%) regions, suggesting a high level of polymorphism throughout the D4Z4 sequences, which might also affect the production of the various D4Z4 transcripts.
Overall, the presence of discrete sites hypomethylated in patients but not in controls or asymptomatic carriers opens new perspectives for mechanistic investigations and identification of regulatory proteins or processes implicated in the pathogenesis and future development of animal models of the disease.
Furthermore, even if DNA methylation is a heritable epigenetic mark, it is also reversible throughout life especially in response to lifestyle, diet, and environment, 31 but can reflect the susceptibility to diseases as exemplified by a number of studies on monozygotic twins, a phenomenon referred to as "epigenetic drift." 32 Our results indicate that D4Z4 methylation is not stably transmitted through generations and that incomplete penetrance in asymptomatic carriers is associated with a level of D4Z4 methylation similar to controls suggesting variability in the transmission of this epigenetic mark and/or somatic variability in affected individuals. At the clinical level, the next step would be to design more targeted approaches that could be applied systematically to patient samples in routine diagnosis, especially in the case of patients with FSHD2 for which the molecular diagnosis is often complex to interpret in the absence of D4Z4 array shortening.
In the context of FSHD, understanding the dynamics of the hypomethylation process may thus provide us with new insights on the disease pathomechanism, and our study also suggests that, in combination with the different 4q35 haplotypes or single nucleotide polymorphisms, 26, [33] [34] [35] the degree of methylation might reflect part of the heterogeneity in the course of the disease and act as a modifier in the clinical expression of this complex muscular dystrophy.
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